CBD cigarettes are cigarettes manufactured from hemp instead of tobacco. The cigarettes contain CBD and a small amount of THC. CBD is a nonpsychoactive compound found in cannabis while THC is the psychoactive compound that induces a high.
Data from a new trial has found that the use of CBD cigarettes is linked to a decrease in patients’ use of antipsychotic drugs. The cigarettes’ effects usually last two to three hours and take between a few seconds and some minutes to set in. This mode of consumption makes it the fastest way to feel CBD’s effects.
The placebo-controlled trial was conducted by an international team of researchers from Germany, Switzerland and Canada. Their findings were reported in the “Frontiers in Psychiatry” journal.
The researchers’ objective was to evaluate the use of CBD cigarettes vs. placebo in a cohort comprised of patients who were acutely psychotic. The patients involved in the study suffered from schizophrenia or other psychotic disorders. For the study, the researchers administered either placebo or CBD to patients every day for 28 days. This was in addition to patients receiving their primary treatments.
Researchers found that both placebo and CBD were linked to similar decreases in symptoms of psychotic disorders and depression. They explained that during treatment, patients who consumed CBD cigarettes used less antipsychotic drugs during the treatment. Conversely, patients who received the placebo treatment increased their use of antipsychotic medication.
In their conclusion, the researchers note that in the multilevel model, the primary group effects were reduced overall use of antipsychotic medications and higher subjective well-being throughout the therapy for the patients that used CBD cigarettes. The researchers add that studies with larger samples and more rigorous study designs need to be conducted in the future to ascertain whether CBD cigarettes can be used as adjunctive therapy with patients suffering from psychotic disorders.
Thus far, research has shown that the administration of CBD has antipsychotic and anxiolytic effects in human subjects. CBD’s use has been linked to changes in brain activity that may decrease some individual’s risk of psychotic episodes.
Clinical trial data that was previously published shows that the daily administration of high CBD doses decreases symptoms of psychotic disorders in patients suffering from schizophrenia. The researchers of the study noted that the 1,000 mg CBD doses decreased symptoms in a manner that was superior to the prescription of amisulpride. Amisulpride is an antipsychotic and antiemetic drug that’s used to treat acute psychotic episodes.
This research is coming at time when a number of companies, including RYAH Group Inc. (CSE: RYAH), have commercialized internet-enabled devices intended to help patients and their doctors measure the precise dosage of plant-based medicines, such as cannabinoids, needed to initiate the beneficial effects sought. Many people are therefore likely to benefit when they use such tools when they take their cannabis medicine.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.